Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

133.52 +2.19 (+1.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
Gilead (GILD) Q1 2026 Earnings Call Transcript ↗
Gilead (GILD) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to... 
Via StockStory
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗
Via Chartmill
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗
Via Chartmill
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year... 
Via StockStory
News headline image
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗
Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations. 
Via Investor's Business Daily
News headline image
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29. 
Via Benzinga
News headline image
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci... 
Via StockStory
Topics Artificial Intelligence
News headline image
Tempus AI (TEM) Q1 2026 Earnings Transcript ↗
Tempus AI (TEM) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 S&P 500 Stock to Own for Decades and 2 We Avoid
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
News headline image
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗
This fixed-income ETF offers diversified bond exposure and a flexible strategy focused on income and sector allocation. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
It may not seem like it at first, but these dividends are safe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
What's Going On With Arcus Biosciences Stock On Wednesday? ↗
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension. 
Via Benzinga
News headline image
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs. 
Via Investor's Business Daily
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers.... 
Via StockStory
Topics Artificial Intelligence
News headline image
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗
Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
News headline image
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗
Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook. 
Via Benzinga
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.